Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie, Instytut Medycyny Doświadczalnej I Klinicznej Im. Mirosława Mossakowskiego PanfiledCriticalUniwersytet Medyczny W Lublinie
Priority to PL406517ApriorityCriticalpatent/PL226845B1/en
Publication of PL406517A1publicationCriticalpatent/PL406517A1/en
Publication of PL226845B1publicationCriticalpatent/PL226845B1/en
Przedmiotem wynalazku jest zastosowanie medyczne kwasu kynureninowego o wzorze ogólnym 1, który wykazuje działanie sodopędne oraz moczopędne, do wytwarzania leku do leczenia zaburzeń gospodarki wodno-elektrolitowej organizmu, a zwłaszcza do leczenia i profilaktyki w zakresie chorób przebiegających z nadmiernym gromadzeniem się płynów w tkankach. Przedmiotem wynalazku jest także kompozycja farmaceutyczna zawierająca kwas kynurenionowy.The subject of the invention is the medical use of kynurenine acid of general formula 1, which has a diuretic and diuretic effect, for the preparation of a medicament for the treatment of disorders of the body's water and electrolyte balance, in particular for the treatment and prevention of diseases involving excessive accumulation of fluid in tissues. The invention also relates to a pharmaceutical composition comprising kynureionic acid.
PL406517A2013-12-132013-12-13Application of kynurenic acid and its salts and pharmaceutical composition
PL226845B1
(en)
compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications; and, pharmaceutical composition.
USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
"compound, pharmaceutical composition, and methods for inhibiting the renal external medullary potassium channel, for causing diuresis, natriuresis or both and for treating one or more disorders".